Matthew Pando, John Jaskowiak, Philippe Rousseau, Bruno Tocque, Douglas Amorese | GenomeWeb
ExonHit Therapeutics said last week that Matthew Pando and John Jaskowiak will join the company’s management board, and Philippe Rousseau will become president of the board until the company appoints a new CEO. Rousseau has been chief financial officer at ExonHit since 2002 and has been a member of its management board since 2004. The firm’s previous CEO and co-founder Bruno Tocque will remain with ExonHit in a consulting position.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.